一个全面更新的神经成像终点在肌缩侧面硬化症的综合性更新
Massimo Filippi1,2,3,4, Alma Ghirelli1,3,4, Edoardo Gioele Spinelli1,3,4
1Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Expert review of neurotherapeutics
|February 22, 2025
概括
神经成像为肌缩侧面硬化症 (ALS) 临床试验提供了有前途的生物标志物. 像MRI和PET这样的技术可以提高患者选择和试验效率,解决更好的ALS治疗的关键需求.
科学领域:
- 神经学 神经学
- 放射学 放射学是一门学科.
- 生物标志物发现发现
背景情况:
- 对于肌缩侧面硬化症 (ALS) 的治疗方法很少,这凸显了改善临床试验终点的需要.
- 目前针对ALS的临床试验缺乏可靠的,标准化的生物标志物来评估治疗疗效.
- 像MRI和PET这样的神经成像技术在ALS试验中显示出患者选择和分层的潜力.
研究的目的:
- 审查神经成像终点在肌缩侧面硬化症 (ALS) 治疗试验中的实用性.
- 探索结构和功能神经影像,肌肉变化和神经炎症作为潜在的生物标志物.
- 讨论这些神经成像替代品在临床试验设计中的实施.
主要方法:
- 使用PubMed.com进行了全面的文献搜索.
- 搜索的重点是过去15年内发表的研究.
- 该审查综合了各种神经成像模式的发现及其与ALS的相关性.
主要成果:
- 神经成像对于理解ALS病理生理学,跟踪疾病进展和评估干预措施至关重要.
- 核磁共振和PET指标可以帮助选择和分层患者,从而可能减少试验时间和成本.
- 该审查涵盖结构/功能神经成像,肌肉/变化以及质/炎症标志物.
结论:
- 神经成像对促进ALS诊断和治疗具有重大潜力.
- 克服成本,可访问性,标准化和患者耐受性等挑战是关键.
- 实施标准化的神经成像生物标志物可以加速开发有效的ALS治疗方法.
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Brain Imaging
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).


